First drug for rare skin cancer wins approvalFDA approved the first treatment for metastatic Merkel cell carcinoma (MCC), a rare, aggressive skin cancer. Top challenges in cancer care January 14, 2017By Tracey WalkerCancer drug costs remain the most critical challenge in care, among other things. Breakthrough lymphoma drug on the horizon November 11, 2016By Christine BlankFDA granted Breakthrough Therapy Designation to brentuximab vedotin (Adcetris, Seattle Genetics) to treat patients with the most common subtypes of lymphoma. Four things health execs should know about the oncology pipelineHere’s how you can recognize changes in the oncology pipeline and maximize value related to cancer care. Merck value rises after new Keytruda approval August 11, 2016By Christine BlankMerck’s Wall Street value is climbing after its cancer drug pembrolizumab (Keytruda) received yet another approval from FDA. Real-world results determine value-based price for specialty drugs July 01, 2016By Marc O'ConnorIn an era when adherence to specialty pharmaceuticals is disturbingly low, value-based pricing needs real-world results, not single-arm accelerated trials. Biosimilars uptake may lag for cancer patients, physicians June 09, 2016By Bryant FurlowBiosimilars will have a significant impact on cancer treatment, with the potential to drive cost savings, but will patients and providers be accepting? Patients demand access to investigational therapies June 07, 2016By Bryant FurlowExpanded access or “compassionate use” programs allow patients to use investigational treatments, medical devices, or tests, before they have received FDA approval. Top 5 facts about cancer drug costs June 03, 2016By Christine BlankThe global oncology market was worth $107 billion in 2015, and global annual cancer drug costs surged by 11.5% from 2011 to 2015, according to a new report. New treatment for kidney cancer gets OK May 25, 2016By Erin BastickFDA has approved lenvatinib (Lenvima, Eisai Inc.) in combination with everolimus for the treatment of advanced renal cell carcinoma.